经皮门静脉穿刺注射IL_2联合TACE治疗肝癌门脉癌栓疗效观察

目的　探讨TACE与经皮肝穿门静脉注射白介素 2联合治疗肝癌并门脉癌栓患者的疗效。方法　 2 2例单纯TACE(对照组 ) ,16例TACE联合经皮门静脉注射IL2 治疗 (治疗组 )治疗肝癌 ,有效率和生存期进行对比分析。结果　肝癌瘤体变化 ,两组无明显差异 ;门脉癌栓 ,对照组消失率 4.5 %,缩小 36 .4%,总有效率 40 .9%,治疗组分别为 12 .5 %、5 0 %、6 2 .5 %;生存率 ,对照组 0 .5、1.0、1.5、2 .0年生存率分别为 45 .5 %、2 7.3 %、0和 0 ,治疗组分别为 5 6 .3 %、31.5 %、12 .5 %、6 .3 %,中位生存期分别为 5 .7M和 8.7M ,1.5、2 .0年生存率对比 (P <0 .0 5 )。结论　TACE联合经皮门静脉注射IL2 可提高肝癌并门脉癌栓的疗效 ,延长生存期。

Observaion on effects of transcanteter arterial embolization and percutaneous injection of IL_2 into portal vein on hepatic carcinoma

Objective To evaluate the effect of TACE companied by percutaneous injection of IL 2 into portal vein on patients with hepatic carcinoma complicated with carcinomatic embolus in portal vein.Methods TACE was performed in 22 cases as control group of TACE combined with portal vein injection of IL 2 were carried out in 16 cases as study group.The effectiveness and survival rate were analysed.Results The change of tumor size were not significant,but carcinoma embolus lessened in 36.4%,resolved in 4.5% in cotral group,as a result,the total effective rate was 40.9%.It lessened in 62.5%,resolved in 12.5% respectvely in the study group.Survival rate of 0.5 year,1,1.5,5 and 2 were 45.5%,27.3%,0%,0%,respectively in the control group but in the study group were 56.3%,37.5%,12.5%,6.3%,respectively.The median of survival term were 5.7 months in control group,but 8.7 months in the study group (P<0.05).Conclusions TACE combined with injection of IL 2 into portal vein is efficient for hepatic carcinoma with portal carcinomatic embolus to increase effective rate and prolong survival term. [